Search Results - Keith W. Pratz

Refine Results
  1. 1
    Acute myeloid leukemia in the elderly: therapeutic options and choice

    Acute myeloid leukemia in the elderly: therapeutic options and choice by Jonathan Webster, Keith W. Pratz

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    How I treat FLT3-mutated AML

    How I treat FLT3-mutated AML by Keith W. Pratz, Mark J. Levis

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Recent advances in targeted therapies in acute myeloid leukemia

    Recent advances in targeted therapies in acute myeloid leukemia by Rahul S. Bhansali, Keith W. Pratz, Catherine Lai

    Published 2023
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia

    Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia by R. Li, N. Sobreira, P. Dane Witmer, Keith W. Pratz, Evan M. Braunstein

    Published 2016
    Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

    FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML by Keith W. Pratz, Takashi Sato, Kathleen M. Murphy, Adam Stine, Trivikram Rajkhowa, Mark J. Levis

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

    Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia by Jessica K. Altman, James M. Foran, Keith W. Pratz, Denise Trone, Jorge E. Cortés, Martin S. Tallman

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients

    Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients by Maria Cristina Villarroel, Keith W. Pratz, Linping Xu, John J. Wright, B. Douglas Smith, Michelle A. Rudek

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study

    Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Phase 1b Study by Alexander E. Perl, Naval Daver, Keith W. Pratz, Joseph Maly, Wan‐Jen Hong, Erkut Bahceci, Bo Tong, Tian Tian, Kimberley Dilley

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies

    Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase–Driven Leukemias and Other Malignancies by J. Kyle Bruner, S. Hayley, Li Li, Alice Can Ran Qin, Michelle A. Rudek, Richard J. Jones, Mark J. Levis, Keith W. Pratz, Christine A. Pratilas, Donald Small

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

    A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response by Keith W. Pratz, Jorge E. Cortés, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark J. Levis

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine

    Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine by Daniel A. Pollyea, Keith W. Pratz, Andrew H. Wei, Vinod Pullarkat, Brian A. Jonas, Christian Récher, Sunil Babu, Andre C. Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda Chyla, Courtney D. DiNardo

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation

    HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation by Amer M. Zeidan, Patrick M. Forde, Heather J. Symons, Allen Chen, Benjamin D. Smith, Keith W. Pratz, Hetty E. Carraway, Douglas E. Gladstone, Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Javier Bolaños‐Meade

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

    Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML by Amy Sexauer, Alexander E. Perl, Xiaochuan Yang, Michael J. Borowitz, Christopher D. Gocke, Trivikram Rajkhowa, Christian Thiede, Mark G. Frattini, Grant E. Nybakken, Keith W. Pratz, Judith E. Karp, B. Douglas Smith, Mark J. Levis

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

    A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms by Joshua F. Zeidner, J. E. Karp, Amanda L. Blackford, B. D. Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Judith M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML)

    Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML) by Keith W. Pratz, Mohamad Cherry, Jessica K. Altman, Brenda Cooper, José C. Cruz, Joseph G. Jurcic, Mark J. Levis, Tara L. Lin, Alexander E. Perl, Nikolai A. Podoltsev, Gary J. Schiller, Chaofeng Liu, Erkut Bahceci

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

    Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia by Marina Konopleva, Michael J. Thirman, Keith W. Pratz, Jacqueline S. Garcia, Christian Récher, Vinod Pullarkat, Hagop M. Kantarjian, Courtney D. DiNardo, Monique Dail, Yinghui Duan, Brenda Chyla, Jalaja Potluri, Catherine L. Miller, Andrew H. Wei

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

    A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias by Keith W. Pratz, E Cho, Mark J. Levis, Judith E. Karp, Steven D. Gore, Michael A. McDevitt, Adam Stine, Ming Zhao, Sharyn D. Baker, Michael A. Carducci, James R. Wright, Michelle A. Rudek, B. Douglas Smith

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy

    Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy by Daniel A. Pollyea, Keith W. Pratz, Brian A. Jonas, Anthony Letai, Vinod Pullarkat, Andrew H. Wei, Marina Konopleva, Christian Récher, Olga Frankfurt, David A. Rizzieri, Tu Xu, Monique Dail, Brenda Chyla, Jalaja Potluri, Courtney D. DiNardo

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

    ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine by Hartmut Döhner, Keith W. Pratz, Courtney D. DiNardo, Brian A. Jonas, Vinod Pullarkat, Michael J. Thirman, Christian Récher, Andre C. Schuh, Sunil Babu, Monique Dail, Grace Ku, Yan Sun, Jalaja Potluri, Brenda Chyla, Daniel A. Pollyea

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study by Daniel A. Pollyea, Keith W. Pratz, Anthony Letai, Brian A. Jonas, Andrew H. Wei, Vinod Pullarkat, Marina Konopleva, Michael J. Thirman, Martha Arellano, Pamela S. Becker, Brenda Chyla, Wan‐Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D. DiNardo

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: